| Author/Editor | Ogrič, Manca; Žigon, Polona; Drobne, David; Štabuc, Borut; Sodin-Šemrl, Snežna; Čučnik, Saša; Praprotnik, Sonja | |
| Title | Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels | |
| Type | članek | |
| Publication year | 2018 | |
| Volume | str. str. | |
| ISSN | 0257-277X - Immunologic research | |
| Language | eng | |
| Abstract | By monitoring serum concentrations of infliximab (IFX) and adalimumab (ADL) and levels of their antibodies in patients with inflammatory diseases, clinicians can adjust dose and increase safety and effectiveness of treatment. The aim was to develop and validate in-house enzyme-linked immunosorbent assays (ELISAs) for IFX and ADL, together with anti-IFX and anti-ADL ELISAs for routine detection and further analysis with acid dissociation of immune complexes. Furthermore, the objectives were to compare in-house assays with commercial ELISAs and reporter gene assays (RGAs) and to determine cross-reactivity between original RemicadeR/RemsimaTM and their antibodies. In-house ELISAs were validated (imprecision, accuracy among other criteria) and compared with commercial apDia ELISAs and RGAs. Correlation coefficients, intraclass correlation coefficients, agreement, and bias were calculated. All in-house ELISAs gave precise and repeatable results. The immune complexes between IFX and anti-IFX were found in 3% of samples, while complexes between ADL and anti-ADL were found in 14% of samples. Significant correlations were found between in-house and apDia ELISAs and RGA for IFX, ADL, anti-IFX, and anti- ADL results. Remicade R, Remsima TM, and their antibodies could be accurately measured with either apDia or in-house IFX and anti-IFX ELISAs. Accurate and precise in-house ELISAs, highly comparable with commercial ELISAs and RGAs, were developed and validated for routine analysis of samples of patients treated with IFX (Remicade R or Remsima TM) or ADL providing substantial cost benefit. Complex dissociation identified samples with anti-IFX-IFX (3%) and anti-ADL-ADL (14%) complexes indicating the benefit of adding acid dissociation to therapeutic drug monitoring of IFX and ADL. | |
| Keywords | infliximab ELISA antibodies infliksimab ELISA protitelesa |